All In Biotech

NDA 202515 · Hospira INC

Morphine Sulfate

Morphine Sulfate · Injection

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Nov 14, 2011

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,053

400 Phase 3, 129 recruiting

FAERS reports

67,702

52,278 serious, 12,172 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE‑THREATENING RISKS FROM USE OF MORPHINE SULFATE INJECTION WARNING: SERIOUS AND LIFE‑THREATENING RISKS FROM USE OF MORPHINE SULFATE INJECTION See full prescribing information for complete boxed warning . • Morphine Sulfate Injection exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) • Serious, life-threatening, or fatal respiratory depression may occur with use of Morphine Sulfate Injection, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ‎Morphine Sulfate ‎Injection are essential. ( 5.2 ) • Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in...

What it is approved for

From the label in effect Oct 14, 2026.

Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Morphine Sulfate Injection is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including Morphine Sulfate Injection, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.‎ ( 1 , 5.1 ) Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death , which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ] , reserve opioid analgesics, including Morphine Sulfate Injection , for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Mechanism: Morphine is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • MORPHINE SULFATE · MORPHINE SULFATE 50MG/ML · INJECTABLE, INJECTION · Prescription
  • MORPHINE SULFATE · MORPHINE SULFATE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MORPHINE SULFATE · MORPHINE SULFATE 4MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MORPHINE SULFATE · MORPHINE SULFATE 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • MORPHINE SULFATE · MORPHINE SULFATE 8MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • MORPHINE SULFATE · MORPHINE SULFATE 2MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Morphine" as an intervention, any sponsor and status, largest first.

All 2,053 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug dependence10,516
  • drug hypersensitivity10,154
  • pain9,236
  • overdose7,799
  • emotional distress5,177
  • nausea4,695
  • dependence4,682
  • drug ineffective4,473
  • death4,265
  • fatigue3,372
  • drug withdrawal syndrome3,367
  • vomiting3,311

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,243
20051,049
2006952
2007529
2008649
2009698
2010892
20111,190
20121,838
20131,464
20141,860
20152,350
20162,902
20172,703
20185,576
20194,345
20203,840
20217,871
20228,454
20238,186
20243,559
20253,350
20262,199

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20). Other

  • Current · updated Nov 9, 2026

    Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01).

  • Current · updated Nov 9, 2026

    Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23). Other

  • Current · updated Nov 9, 2026

    Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01).

  • Current · updated Nov 9, 2026

    Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01). Other

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Morphine Sulfate* (Morphine Sulfate)

2024 spending

$17.1M

Beneficiaries

240,437

721,076 claims

Per beneficiary

$71

$0.39 per unit

View as table
YearSpending
2020$23,761,810
2021$20,733,114
2022$19,694,207
2023$18,551,347
2024$17,055,438

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8,877 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.